Potentiation of melphalan by systemic hyperthermia in mice: therapeutic gain for mouse lung microtumours.
The effect of systemic hyperthermia at 41 degrees C on the response to melphalan (Mel) of KHT and RIF-1 lung microtumours was studied. Mice with KHT microtumours were treated on day 3 or 4 after inoculation and mice with RIF-1 microtumours on day 4. Results were compared with previously published data for 300-600 mm3 leg tumours and normal marrow stem cells, and therapeutic ratios (TR) were calculated. Therapeutic gain was found for both tumours but in RIF-1 at higher doses only, with TRs from 1.1 to 1.6 for KHT microtumours and from 0.8 to 1.4 for RIF-1. TR values were rather smaller for lung microtumours than leg tumours but the change in slope of the Mel dose response curve by heat was very similar. The results are discussed in the light of the likely difference of tumour milieu between leg tumours and lung microtumours.
D000818:Animals; D003131:Combined Modality Therapy; D005260:Female; D005354:Fibrosarcoma / Q000628:therapy; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D012513:Sarcoma, Experimental / Q000628:therapy; D014410:Tumor Stem Cell Assay
D008558:Melphalan